AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

13.74 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022

April 26, 2022

From AbCellera Biologics Inc.

Via Business Wire

3 Biotech Stocks Under $10 to Add to Your Buy List ↗

April 26, 2022

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk.

Via InvestorPlace

AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022

April 12, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Presents Data on T Cell Engager Platform at AACR 2022

April 08, 2022

From AbCellera Biologics Inc.

Via Business Wire

Sunday Memo - Dec. 5 ↗

December 05, 2021

The market rout was worldwide last week.

Via Talk Markets

AbCellera Reports Full Year 2021 Business Results

February 24, 2022

From AbCellera Biologics Inc.

Via Business Wire

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

February 23, 2022

From AbCellera Biologics Inc.

Via Business Wire

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19 ↗

February 14, 2022

The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized...

Via Benzinga

AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19

February 11, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022

February 11, 2022

From AbCellera Biologics Inc.

Via Business Wire

Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments

February 10, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

January 27, 2022

From AbCellera

Via Business Wire

Top Biotech Stocks: Trading Opportunities For Next Week ↗

December 19, 2021

A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns.

Via Talk Markets

AbCellera Announces Changes to Its Board of Directors

December 07, 2021

From AbCellera Biologics Inc.

Via Business Wire

Futures Rebound From Friday Rout As Omicron Fears Ease ↗

December 06, 2021

S&P futures and European stocks rebounded from Friday’s selloff while Asian shares fell, as investors took comfort in reports from South Africa which said initial data doesn’t show a surge of...

Via Talk Markets

Topics Stocks

Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns ↗

December 06, 2021

The FDA has expanded the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) bamlanivimab and etesevimab administered together to include...

Via Benzinga

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

December 03, 2021

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

December 02, 2021

From AbCellera Biologics Inc.

Via Business Wire

Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail? ↗

November 29, 2021

Smaller companies are working on next-generation approaches to Covid treatment.

Via Investor's Business Daily

These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19 ↗

November 29, 2021

Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

Friday Markets Coverage ↗

November 19, 2021

Today markets are suffering alongside Austria which locked down against Covid-19 again.

Via Talk Markets

AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript ↗

November 10, 2021

ABCL earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

AbCellera Reports Q3 2021 Business Results

November 09, 2021

From AbCellera Biologics Inc.

Via Business Wire

How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed ↗

November 09, 2021

Benzinga Pro data, AbCellera Biologics (NASDAQ:ABCL) reported Q2 sales of $27.64 million. Earnings fell to a loss of $7.03 million, resulting in a 104.45% decrease from last...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

AbCellera Announces Virtual Presentations at Investor Conferences in November

November 04, 2021

From AbCellera Biologics Inc.

Via Business Wire

Why AbCellera Biologics Stock Sank 21.6% in October ↗

November 04, 2021

The biotech is now down roughly 56% across 2021's trading.

Via The Motley Fool

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19

November 02, 2021

From AbCellera Biologics Inc.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.